Market capitalization | $1.17b |
Enterprise Value | $850.90m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 13.35 |
P/S ratio (TTM) P/S ratio | 18.32 |
P/B ratio (TTM) P/B ratio | 3.67 |
Revenue growth (TTM) Revenue growth | 9.03% |
Revenue (TTM) Revenue | $63.72m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
12 Analysts have issued a Ocular Therapeutix Inc forecast:
12 Analysts have issued a Ocular Therapeutix Inc forecast:
Dec '24 |
+/-
%
|
||
Revenue | 64 64 |
9%
9%
|
|
Gross Profit | 58 58 |
9%
9%
|
|
EBITDA | -168 -168 |
112%
112%
|
EBIT (Operating Income) EBIT | -172 -172 |
109%
109%
|
Net Profit | -194 -194 |
140%
140%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
Head office | United States |
CEO | Pravin Dugel |
Employees | 274 |
Founded | 2006 |
Website | www.ocutx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.